S-1: Caring Brands Files S-1 for Nasdaq Listing & Public Offering

Caring Brands, Inc., a wellness consumer products company, has filed an S-1 registration statement for a public offering of up to 1,000,000 shares of common stock and the resale of 2,710,000 shares by selling stockholders, aiming for a Nasdaq Capital Market listing.

Summary

• Caring Brands, Inc. is a wellness consumer products company offering over-the-counter (OTC) and cosmetic products, including Photocil (for vitiligo and psoriasis), Hair Enzyme Booster (JW-700), CB-101 (eczema treatment), and NoStingz (sunscreen/jellyfish sting protection).
• The company is seeking to raise approximately $3,200,000 in net proceeds from the public offering of 1,000,000 shares at an assumed price of $4.00 per share, with an option for underwriters to purchase an additional 150,000 shares.
• A separate resale prospectus covers up to 2,710,000 shares held by selling stockholders, including 2,110,000 warrant shares from private placements and 600,000 shares distributed by former parent Safety Shot, Inc.
• The company was incorporated in Nevada on April 23, 2024, as part of a separation from Safety Shot, Inc. (formerly Jupiter Wellness Inc.), which retains approximately 22.5% ownership.
• Financial results show nominal revenue of $3,056 and a net loss of $1,199,353 for the six months ended June 30, 2025, and a net loss of $1,517,431 for the year ended December 31, 2024.
• As of June 30, 2025, cash and cash equivalents were $73,893, and the company has an accumulated deficit of $2,062,144, raising substantial doubt about its ability to continue as a going concern.
• Key products like Photocil and NoStingz were previously removed from the U.S. market due to insufficient sales and lack of dedicated sales/marketing teams, with relaunch targeted for 2026.
• The Hair Enzyme Booster (JW-700) was launched on Amazon in October 2024 and NOVODX's e-commerce platform in December 2024, with minimal initial sales.
• The company has licensing agreements for JW-700 and Photocil in India and 31 other territories with Cosmofix and San Pellegrino Cosmetics, and an exclusive license for JW-700 in Japan with Taisho Pharmaceutical Co., Ltd.
• A Research Collaboration and Non-Exclusive License Agreement was entered into with NOVODX Corporation on June 20, 2024 (amended July 22, 2024), for an Ebola Rapid Test, involving a stock issuance and future milestone payments/royalties contingent on FDA approval and sales.
• The company plans to use offering proceeds for product development, including reformulation of CB-101 ($150,000), initial production ($200,000), and clinical testing ($50,000), targeting a Q2 2026 online launch for CB-101.

Sentiment

Score: 3

Explanation: The company is in an early stage with a limited operating history and has incurred significant recurring losses, raising substantial doubt about its ability to continue as a going concern. While there are promising product pipelines, clinical trial results, and market growth projections, the financial instability and past commercialization challenges for key products present high risks. The success of the IPO and future operations is highly contingent on securing additional capital and effective execution of relaunch and marketing strategies.

Positives

• The global phototherapy treatment market is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033, at a CAGR of around 5.2%.
• The Indian phototherapy market is expected to expand even faster, with an estimated CAGR of approximately 7.8% as of 2023.
• The global psoriasis treatment market was worth approximately $34 billion globally in the 12 months ending June 2023, with the U.S. accounting for approximately 78% of total sales and growing at an 18% CAGR.
• The global psoriasis market is expected to reach approximately $54-67 billion by 2030, with a CAGR of 8-10% from 2023.
• The global vitiligo treatment market was valued at approximately $538.90 million in 2024 and is projected to grow at a CAGR of 4.60% from 2025 to 2034, reaching approximately $807.70 million by 2034.
• Photocil has been evaluated in clinical trials for vitiligo and psoriasis, demonstrating significant efficacy, with one vitiligo trial showing 28% achieved 70% re-pigmentation and a p-value of <0.0001.
• A psoriasis trial for Photocil showed 43% achieved complete clearance and a mean lesion clearance of 75%, with a p-value of <0.00012.
• The Hair Enzyme Booster (JW-700) has been clinically shown to increase sulfotransferase enzymes needed for minoxidil to work, with a 124% increase in SULT1A1 activity in one trial and 75% of subjects showing increased enzyme activity in another.
• The Hair Enzyme Booster (JW-700) has 2 granted and 5 pending patents.
• The minoxidil market was valued at $1.5 billion in 2022 and is expected to grow to $2.5 billion by 2032.
• The Hair Enzyme Booster (JW-700) is licensed to Taisho, a $2.6 billion revenue company and Japan's leading seller of minoxidil products, with commercial launch expected in 2025, including up to $200,000 in milestone payments and a 3% royalty.
• CB-101 (eczema treatment) showed promising results in clinical studies of its prior formulation (JW-100), clearing or reducing eczema in 50% of subjects with a two-grade improvement compared to 15% in the placebo group (p=0.028).
• The global eczema treatment market was valued at $14 billion in 2022.
• NoStingz, a sunscreen product designed to protect against UV rays and jellyfish stings, demonstrated promising initial results in reducing sting severity in a small preliminary trial.
• The company has secured $2,110,000 in gross proceeds from a private placement (Bridge Financing) between April and June 2024.
• The separation from Safety Shot, Inc. is expected to provide increased strategic and operational flexibility, focused management, and independent equity currency for acquisitions and incentives.
• The company intends to apply to list its common stock on The Nasdaq Capital Market (NASDAQ) under the symbol CBRA, which would enhance market visibility and liquidity.

Negatives

• The company has a limited operating history, making it difficult to accurately evaluate business prospects and forecast future revenues.
• Photocil was removed from the U.S. market in February 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team.
• The Hair Enzyme Booster (JW-700) had minimal sales during its initial soft launch period on Amazon and NOVODX's e-commerce platform.
• CB-101 eczema treatment development is on hold pending reformulation.
• NoStingz was removed from the U.S. market in September 2023 due to insufficient sales resulting from the lack of a dedicated sales and marketing team.
• The company has incurred recurring losses from operations, generated negative cash flows from operating activities, and has an accumulated deficit of $2,062,144 as of June 30, 2025.
• The company's financial situation creates substantial doubt about its ability to continue as a going concern.
• There is no assurance that sufficient funds required will be generated from operations or available from external sources, which could force the company to curtail or cease operations.
• The company may not be able to successfully compete against companies with substantially greater resources and brand recognition in the competitive skin care and hair growth product markets.
• The distribution of shares by Safety Shot to its stockholders is expected to be a taxable event for both Safety Shot and its stockholders.
• The company will bear significant incremental costs associated with being a publicly-held company and may need to absorb certain corporate and operational support costs previously provided by Safety Shot.
• The company's common stock may become subject to the SEC's penny stock rules if not listed on a national securities exchange, which could adversely affect trading activity.
• The company does not intend to pay dividends for the foreseeable future.

Risks

• The company may be unable to achieve some or all of the benefits expected from the separation from Safety Shot, Inc.
• The company may be unable to make, on a timely or cost-effective basis, the changes necessary to operate as a publicly traded company, and may experience increased costs after the separation.
• The distribution of shares by Safety Shot, Inc. may not qualify as a generally tax-free transaction for U.S. federal income tax purposes, potentially subjecting Safety Shot and its stockholders to significant tax liabilities.
• Conflicts of interest may arise due to some directors and executive officers owning Safety Shot common stock or holding positions with Safety Shot, Inc.
• The company has a limited operating history, making it difficult to accurately evaluate business prospects and forecast future revenues.
• The company's financial situation creates doubt about its ability to continue as a going concern, and there is no assurance of obtaining adequate additional funding.
• Failure to secure additional financing in a timely manner and on favorable terms would have a material adverse effect on financial performance and may require curtailing or ceasing operations.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies or assets.
• The company may be unable to keep up with rapid technological changes, potentially rendering its products obsolete.
• Competition from companies with substantially greater resources could adversely affect the business.
• Failure to develop and maintain brand and reputation for product offerings could materially harm the business.
• Dependence on key personnel and potential turnover could harm the business.
• Unfavorable changes in government regulation could substantially harm the business and results of operations.
• Products may not meet health and safety standards or could become contaminated, leading to recalls and liability claims.
• The sale of products involves product liability and related risks that could expose the company to significant insurance and loss expenses.
• The market opportunities for current and potential future drug candidates may be smaller than believed, adversely affecting revenue generation.
• Inability to establish relationships with licensees or collaborators for sales, marketing, and distribution, or to create effective in-house capabilities, could hinder market success.
• The ability to market products in the United States depends on regulatory classification and compliance, and the FDA may disagree with the company's determinations.
• Commercial success of OTC/Cosmetic product candidates depends on acceptance by physicians, payers, and patients, which is uncertain.
• If FDA approval is obtained for any product candidates, the company will be subject to various federal and state fraud and abuse laws, which may increase operating costs.
• Natural disasters and other events beyond control could materially adversely affect the company's operations.
• Failure to meet product development and commercialization milestones could delay schedules and impact sales.
• Manufacturing operations could be disrupted by various factors, including supply chain issues or natural disasters.
• Operations in international markets involve inherent risks, including macroeconomic conditions, foreign currency exchange rates, political instability, and regulatory requirements.
• The company may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.
• Inability to adequately protect intellectual property could reduce the value of products and brands, affecting profitability.
• The intellectual property behind products may include unpublished know-how dependent on key individuals, and patent protection eventually expires.
• As an emerging growth company, reduced disclosure requirements may make common stock less attractive to investors.
• The requirements of being a public company may strain resources and distract management.
• Management has limited experience in managing day-to-day operations of a public company, potentially leading to additional expenses.
• Compliance with changing corporate governance regulations and public disclosures may result in additional risks and exposures.
• Significant percentage of voting securities held by certain stockholders could reduce the ability of minority stockholders to effect corporate actions.
• Inaccurate or unfavorable research by securities or industry analysts could cause stock price decline.
• Issuance of additional common stock or preferred stock may cause common stock price to decline and dilute existing stockholders.
• Common stock may become subject to SEC's penny stock rules, making it difficult to complete customer transactions.
• Inability to implement and maintain effective internal control over financial reporting could lead to loss of investor confidence.
• Concurrent resale and potential dilution of stockholders' ownership due to the resale prospectus could adversely impact market price, liquidity, and demand.
• No active, liquid, and orderly trading market may develop for common stock, making it difficult to sell shares.
• Inability to satisfy Nasdaq listing requirements or obtain/maintain listing could impair ability to raise capital and affect investment value.
• Investing in the company is highly speculative and could result in the entire loss of investment.
• Anti-takeover provisions in the company's charter and bylaws may prevent or frustrate attempts by stockholders to change the board or management.

Future Outlook

The company plans to relaunch Photocil in the U.S. in 2026 and complete reformulation and launch CB-101 online in the U.S. in Q2 2026. It intends to expand its sales and marketing team, enhance its e-commerce platform, and establish retail distribution strategies. The company will also explore acquisition opportunities in the branded consumer products space, focusing on OTC/cosmetic therapeutic and skincare brands. Commercial launch of Hair Enzyme Booster in Japan by Taisho is expected in 2025. The company is evaluating market opportunities for the Ebola Rapid Test and is in preliminary discussions for licensing opportunities in Europe and South America.

Management Comments

• Glynn Wilson was appointed as CEO due to his demonstrated success in leading public companies and approach to transforming scientific innovation into market-ready solutions, ensuring the company can capitalize on innovations and navigate complex regulatory and market environments.
• Brian S. John was appointed as Executive Chairman due to his proven track record in driving business growth, entrepreneurial spirit, and ability to navigate complex financial landscapes, with deep understanding of markets and experience in launching and managing publicly traded companies.
• Markita L. Russell was appointed as CFO due to her extensive experience in managing financial operations and expertise in SEC compliance and reporting, positioning her as a key figure in ensuring fiscal integrity and operational efficiency.
• Dr. Hector Alila was appointed to the board because of his exceptional expertise in drug development and work in cancer therapeutics, bringing invaluable experience to guide the company's growth.
• Christopher Galeta was selected as a director because of his extensive legal experience with contracts and business agreements, providing valuable perspective to the Board.
• Christopher Melton was appointed to the board due to his extensive investment experience, strong background in finance and portfolio management, and critical oversight and governance experience as Audit Chair.

Industry Context

Caring Brands operates within the wellness consumer products industry, specifically targeting the over-the-counter (OTC) and cosmetic segments. The company's product pipeline addresses significant and growing markets such as hair loss, eczema, psoriasis, and vitiligo. The filing highlights substantial global market growth projections for phototherapy treatments (5.2% CAGR), psoriasis treatments (8-10% CAGR), and vitiligo treatments (4.60% CAGR), indicating a favorable industry backdrop for its core products. The minoxidil market, which its Hair Enzyme Booster aims to enhance, is also projected for significant growth. The company's strategy of focusing on products with established mechanisms of action, clinical trial efficacy, and patent protection aligns with industry trends emphasizing evidence-based consumer health solutions. However, the industry is highly competitive, with larger, more established players, and barriers to entry for new products are relatively low, requiring strong brand development and marketing efforts.

Comparison to Industry Standards

• Photocil's narrow-band UV filter technology is presented as proprietary and not found in other sunscreens, differentiating it from conventional UV blockers.
• Photocil's clinical trial results for vitiligo (28% achieved 70% re-pigmentation, p<0.0001) and psoriasis (43% complete clearance, mean 75% clearance, p<0.00012) are highlighted as demonstrating significant efficacy, positioning it against conventional phototherapy lamp treatments by offering a more convenient topical home-use option.
• The Hair Enzyme Booster (JW-700) is designed to improve the efficacy of FDA-approved minoxidil, rather than being a standalone hair growth treatment, differentiating it from many non-FDA approved nutritional supplements in the hair growth market.
• The licensing deal with Taisho Pharmaceutical Co., Ltd., a $2.6 billion revenue company and Japan's leading minoxidil supplier, suggests a strong industry validation for the Hair Enzyme Booster's potential in enhancing minoxidil's effectiveness.
• CB-101's prior formulation (JW-100) showed a 1.28 ISGA score reduction compared to 0.70 in the placebo group (p=0.042) for eczema, with 50% achieving clear/almost clear with two-grade improvement vs. 15% for placebo (p=0.028), suggesting potential superiority to existing prescription drugs.
• The company acknowledges that Psoriasis and Vitiligo treatments with Photocil may only address a very small fraction of the total global market, indicating a realistic assessment of market penetration compared to the broader industry.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not a party to any pending legal proceeding, nor is its property the subject of a pending legal proceeding, that is not in the ordinary course of business or otherwise material to the financial condition of its business.
• None of the directors, officers or affiliates are involved in a proceeding adverse to the business or have a material interest adverse to the business.

Related Party Transactions

• The company was incorporated for the purpose of separating its business operations from Safety Shot, Inc. (formerly Jupiter Wellness Inc.), which previously owned a majority of Caring Brands Florida's shares and provided administrative services.
• Safety Shot, Inc. owns 3,000,000 shares of the company's common stock, representing approximately 22.5% of outstanding shares, and will distribute 600,000 of these shares to its stockholders.
• The Separation and Exchange Agreement governs the separation, including the transfer of the CB Business and related assets/liabilities to Caring Brands, Inc., and the waiver of a $275,876 outstanding loan balance from Safety Shot to Caring Brands Florida.
• Nancy Torres, a former director of Safety Shot and a current director of Caring Brands, is the CEO of NOVODX Corporation, a related party.
• In May 2024, NOVODX Corporation participated in the company's private placement, acquiring 500,000 shares of common stock for $500,000.
• In June 2024, the company invested $500,000 in NOVODX Corporation's private placement, purchasing 25,134 shares (less than 1% ownership).
• On June 20, 2024 (amended July 22, 2024), the company entered into a Research Collaboration and Non-Exclusive License Agreement with NOVODX Corporation for an Ebola Rapid Test, involving the issuance of 3,000,000 shares of restricted common stock to NOVODX.
• The NOVODX license agreement includes an initial cash payment of $100,000 due within 30 days of the S-1 effectiveness, and milestone payments of $1,000,000 upon 510K/EUA approval and $500,000 when annual net sales reach $5 million, plus royalties of 5% (under $500M net sales) and 3% (over $500M net sales).
• The company entered into a short-term loan with one of its founders in June 2025 and another with its chairman of the board in July 2025, both due October 30, 2025, with an 8% interest rate.
• The company shares office premises with Safety Shot, Inc., with an agreement for continued presence until mutual agreement on separate facilities or a sub-lease arrangement.

Stakeholder Impact

• **Shareholders:** Existing shareholders will experience dilution from the public offering and potential future capital raises. The investment is highly speculative with a high degree of risk, including the potential loss of the entire investment. The separation from Safety Shot aims to create a more focused investment profile.
• **New Investors:** New investors in the public offering will experience immediate dilution of $3.77 per share based on the assumed $4.00 offering price, as the pro forma as adjusted net tangible book value is $0.23 per share.
• **Employees:** The separation from Safety Shot is intended to facilitate incentive compensation arrangements more directly tied to the company's performance and enhance employee hiring and retention.
• **Customers:** The company aims to provide innovative wellness consumer products, with planned relaunches and new product introductions, potentially offering new treatment options for various conditions.
• **Suppliers/Manufacturers:** The company relies on third-party manufacturers (Stella Industries Ltd., DCR Labs) and raw material suppliers, making them critical to product availability and quality. Disruptions could impact product supply.
• **Creditors:** The company's going concern doubt and recurring losses indicate potential challenges in meeting financial obligations, which could impact creditors.

Next Steps

• Complete the public offering and list common stock on The Nasdaq Capital Market (NASDAQ) under the symbol CBRA.
• Utilize net proceeds from the offering for general and working capital purposes, including investing in research and development.
• Set up manufacturing and develop initial marketing materials for Hair Enzyme Booster (JW-700) by Q1 2026, followed by a full marketing campaign rollout and expansion to additional e-commerce platforms and retail distribution.
• Initiate preparation for scaling-up Photocil manufacturing between Q3 and Q4 2025.
• Initiate the FDA registration process for Photocil by Q4 2025, with U.S. market relaunch and e-commerce platform integration planned for Q4 2025/Q1 2026.
• Initiate reformulation process for CB-101 in Q4 2025, aiming for completion by Q1 2026.
• Initiate production run and clinical testing for CB-101 by Q2 2026, with marketing materials development, U.S. market relaunch, and e-commerce platform integration by Q3 2026.
• Complete reformulation and initiate stability testing for NoStingz by Q4 2025, followed by FDA registration process by Q1 2026 and initial production.
• Evaluate market opportunities for the Ebola Rapid Test and determine its development timeline and costs.
• Explore additional sub-licensing opportunities for Photocil in various international markets (Nepal, Bangladesh, Sri Lanka, Vietnam, Philippines, Malaysia, Cambodia, Laos, Indonesia, UAE, Egypt, Algeria, Tunisia, Congo, Nigeria, Kenya, Thailand, Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Qatar, and Saudi Arabia).
• Continue preliminary discussions regarding potential licensing opportunities in Europe and South America.
• Maintain compliance with all applicable regulatory requirements for OTC and cosmetic products in the U.S. and internationally.
• Continually update and expand the corporate website and refine online retail strategies.

Key Dates

Recommendation

Caring Brands, Inc. is an early-stage company with a promising product pipeline in growing wellness markets, supported by positive clinical trial data for some products and strategic licensing agreements. The planned Nasdaq listing and capital raise could provide necessary funding for product development and commercialization. However, the company has a limited operating history, significant recurring losses, and a 'going concern' warning from its auditors, indicating substantial financial risk. Past commercialization failures for key products highlight execution challenges. Given the high speculative nature and the need for successful execution of its ambitious relaunch and marketing plans, a 'Hold' recommendation is appropriate. Investors should monitor progress on product relaunches, market adoption, and financial stability before considering further investment.

Keywords

Wellness Consumer Products, OTC Products, Cosmetic Products, Psoriasis Treatment, Vitiligo Treatment, Hair Loss Treatment, Eczema Treatment, Jellyfish Sting Protection, Photocil, Hair Enzyme Booster, CB-101, NoStingz, Ebola Rapid Test, Nasdaq Listing, Public Offering, SEC S-1, Biotechnology, Dermatology, OTC Drugs, Clinical Trials, Intellectual Property, Licensing Agreements, Going Concern, Capital Raise, Emerging Growth Company